New Treatment Guidelines for Neuropsychiatric Conditions

New comprehensive treatment recommendations to help guide the management of youngsters with neuropsychiatric conditions have been developed by a panel of leading clinicians and researchers across various general and specialty pediatric fields, reveals a new study. //

Neuropsychiatric conditions are defined by the terms Pediatric Acute Onset Neuropsychiatric Syndrome (PANS) and PAN Disorder Associated with Streptococcal Infection (PANDAS). //

Mechanism That Alters Neural Excitability Linked With Neuropsychiatric Disorders
The well-known mechanism of gene expression control - dynamic changes in DNA methylation - is also involved in changes to the excitability of neural cells.

‘Guidelines developed for treating neuropsychiatric conditions such as PANS and the PANDA relieves symptoms, eliminates the source of infection and neuroinflammation.’

Tweet it Now

The treatment recommendations, focusing mainly on psychiatric and behavioral interventions, treatment and prevention of infections, and immunomodulatory therapies are published in a special issue of Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers .

The treatment guidelines are available free on the Journal of Child and Adolescent Psychopharmacology website.

The special issue on PANS/PANDAS treatment guidelines was led by Guest Editors Jennifer Frankovich, MD, Stanford University (Palo Alto, CA), Susan Swedo, MD, National Institutes of Health (Bethesda, MD), and Tanya Murphy, MD, University of South Florida (St. Petersburg).

How Recurrent Strep A Infections Enter Brain to Cause Neuropsychiatric Disorders
Researchers have discovered how immune cells triggered by Strep A infections enter brain, causing inflammation that lead to autoimmune neuropsychiatric disorders.

Three articles in the issue are entitled "Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS):" followed by "Part I-Psychiatric and Behavioral Interventions;" "Part II-Use of Immunomodulatory Therapies;" and "Part III-Treatment and Prevention of Infections."

In "Part I-Psychiatric and Behavioral Interventions," Margo Thienemann, MD, Stanford University and coauthors present consensus guidelines for treating the psychiatric and behavioral symptoms of children with PANS/PANDAS. Symptom improvement is aimed at decreasing suffering, improving functioning, and making it easier for the children to adhere to therapeutic interventions.

Understanding the Underpinnings of Neuropsychiatric Disorders
Duplications or deletions of DNA along 22nd chromosome hint at biological underpinnings of neuropsychiatric disorders.

In "Part II-Use of Immunomodulatory Therapies," Jennifer Frankovich, MD, and coauthors provide recommendations to help guide the use of therapies targeting the neuroinflammation and post-infectious autoimmunity that are common in PANS-PANDAS.

In "Part III-Treatment and Prevention of Infections," Michael Cooperstock, MD, MPH, University of Missouri School of Medicine (Columbia) and coauthors representing the PANS PANDAS Consortium, present a consensus guideline for managing the infection components of these neuropsychiatric conditions.

Smoking Cessation Drugs Do Not Cause Any Neuropsychiatric Effects
There are 1 billion smokers in the world and nearly 6 million smoking-related deaths each year, but drugs aiding smoking cessation are very few.

Drs. Swedo, Frankovich, and Murphy, in their Introduction to the special issue summarize the therapeutic challenges in treating PANS and the PANDAS subset, the development of the guidelines, and the three-pronged therapeutic approach that may combine psychiatric medications to relieve symptoms, antibiotics to eliminate the source of infection and neuroinflammation, and anti-inflammatory and immunomodulatory therapies that target the immune system.

"We are very pleased to be able to provide the state of the art in clinical management of PANS and PANDAS in this issue of our journal," says Harold S. Koplewicz, MD, editor in chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.

Research reported in this publication was supported by the National Institutes of Health under Award Numbers 1R01MH093381-01A1, 1R21MH087849-01A1, 1R01HD080096-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Source-Eurekalert